Les informations présentées dans l’Outil de recherche personnalisé d’essais cliniques de Myélome Canada sont issues de la base de données des essais cliniques internationaux du site
ClinicalTrials.gov,
répertoriées par la U.S. National Library of Medicine. Bien que le menu soit en français, les détails des études ne sont offerts qu’en anglais.
Study of BMS-986393 a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL)
*Les informations de l'essai contenues sur cette page ont été récupérées du site ClinicalTrials.gov. Cliquez ici pour voir cet essai sur ClinicalTrials.gov.
- Titre complet:
- A Phase 2, Open-Label, Multicenter Study of BMS-986393, a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL)
- Stade ou Condition:
- Multiple Myeloma
- Phase d'étude:
- Phase 2
- Résumé:
- The purpose of this study is to evaluate the effectiveness and safety of BMS-986393 in participants with relapsed or refractory multiple myeloma.
- Description détaillée:
- Non disponible
- Traitements:
- Biological : BMS-986393
Specified dose on specified days
- Groupes d'étude:
- Experimental : BMS-986393
- Type d'étude:
- Interventional
- Protocole de l'étude:
- Allocation: N/A
- Intervention Model: Single Group Assignment
- Primary Purpose: Treatment
- Masking: None (Open Label)
- Statut du recrutement:
- En cours
- Critères d'admissibilités:
-
sion Criteria
- Documented diagnosis of multiple Mmyeloma (MM) as per International Myeloma Working Group (IMWG) criteria.
- Received at least 4 classes of MM treatment [including immunomodulatory drug (IMiD), proteasome inhibitor (PI), anti CD38 mAb, and anti-B cell maturation antigen (BCMA) therapy], and at least 3 prior lines of therapy (LOT).
- Documented disease progression during or after their last anti-myeloma regimen as per IMWG.
- Participants must have measurable disease during screening.
- Have measurable disease during screening.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Exclusion Criteria
- Active or history of central nervous system involvement with MM.
- Active systemic fungal, bacterial, viral, or other infection despite appropriate anti-infective treatment at the time of leukapheresis.
- Received any prior therapy directed at G protein-coupled receptor class C, group 5, member D (GPRC5D) or has received other prior treatment for MM without the required washout prior to leukapheresis.
- Other protocol-defined Inclusion/Exclusion criteria apply.
- Lieux / Centres:
-
Local Institution - 0020, Calgary, Alberta – À venir
Local Institution - 0021, Montréal, Quebec – À venir
- Contacts:
- Name: BMS Study Connect Contact Center www.BMSStudyConnect.com
Phone: 855-907-3286
Email: [email protected]
- Publications:
- ???
- Date d’affichage:
- 2024-03-07
- Date de début:
- March 21, 2024
- Dernière mise à jour:
- 2024-05-09
- Nombre d'inscriptions anticipées:
- 150
- Date de fin prévue:
- 2030-06-04
- Date de fin prévue de l'étude primaire:
- 2026-10-02
- Condition:
- Multiple Myeloma
- Genre:
- All
- Âge:
- 18 Years-N/A
- Accepte des bénévoles en santé:
- No
- Pays participants:
- Canada
- United States
- Numéro d’identification:
- NCT06297226
- Autres numéros d'identification de l'étude:
- CA088-1000
- Comité de suivi des données:
- Yes
- Produit réglementé par la FDA (É-U):
- Yes
- IPD Sharing Statement :
- ???
- Responsables de l’étude:
-
Sponsor
- Commanditaires de l’étude:
- lead_sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Industry
- Collaborators:
- ???
- Chercheurs:
- Bristol-Myers Squibb Bristol-Myers Squibb
- Protocol Registration and Results System:
- ???
- Date de vérification:
- 2024-05-01